abrdn Life Sciences Investors (HQL)
About abrdn Life Sciences Investors
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $514.5M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $514.5M
- Dividend yield
- 11.64%
- Shares outstanding
- 26.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 1, 1992
abrdn Life Sciences Investors (HQL) Stock Price
- Trading 8% below its 52-week high.
- Pays a dividend yielding about 11.64% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review abrdn Life Sciences Investors.
Write a review
News about abrdn Life Sciences Investors
News & sentiment via Polygon.io
abrdn Life Sciences Investors: frequently asked questions
Is abrdn Life Sciences Investors an American company?
abrdn Life Sciences Investors is a US-based company headquartered in Philadelphia, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is abrdn Life Sciences Investors headquartered?
abrdn Life Sciences Investors is headquartered in Philadelphia, Pennsylvania, United States.
Is abrdn Life Sciences Investors publicly traded?
Yes — abrdn Life Sciences Investors is a publicly traded company. Its stock trades under the ticker symbol HQL on the NYSE.
